GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (NAS:LIVN) » Definitions » Cash-to-Debt

LIVN (LivaNova) Cash-to-Debt : 0.52 (As of Sep. 2024)


View and export this data going back to 1993. Start your Free Trial

What is LivaNova Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. LivaNova's cash to debt ratio for the quarter that ended in Sep. 2024 was 0.52.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, LivaNova couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for LivaNova's Cash-to-Debt or its related term are showing as below:

LIVN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16   Med: 0.39   Max: No Debt
Current: 0.49

During the past 13 years, LivaNova's highest Cash to Debt Ratio was No Debt. The lowest was 0.16. And the median was 0.39.

LIVN's Cash-to-Debt is ranked worse than
72.18% of 859 companies
in the Medical Devices & Instruments industry
Industry Median: 1.83 vs LIVN: 0.49

LivaNova Cash-to-Debt Historical Data

The historical data trend for LivaNova's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

LivaNova Cash-to-Debt Chart

LivaNova Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.36 0.73 0.37 0.42

LivaNova Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.42 0.46 0.49 0.52

Competitive Comparison of LivaNova's Cash-to-Debt

For the Medical Devices subindustry, LivaNova's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LivaNova's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where LivaNova's Cash-to-Debt falls into.



LivaNova Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

LivaNova's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

LivaNova's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LivaNova  (NAS:LIVN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


LivaNova Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of LivaNova's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


LivaNova Business Description

Traded in Other Exchanges
Address
20 Eastbourne Terrace, London, GBR, W2 6LG
UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Executives
Francesco Bianchi director C/O LIVANOVA PLC, 5 MERCHANT SQUARE, LONDON X0 W2 1AY
Daniel Jeffrey Moore director 100 CYBERONICS BVLD, HOUSTON TX 77058
James Christopher Barry director 7475 LUSK BLVD, SAN DIEGO CA 92121
Damien Mcdonald officer: COO 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Michael Damon Hutchinson officer: Chief Legal Officer 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Brooke Story director C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET, SUITE 600, CAMBRIDGE MA 02142
Peter M Wilver director
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
William A Kozy director C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Marco Dolci officer: SVP Global Operations, R&D VIA BENIGNO CRESPI 17, MILAN L6 20159
Todd C Schermerhorn director C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Alex Shvartsburg officer: Interim CFO 20 EASTBOURNE TERRACE, LONDON X0 W26LG
Roy Khoury officer: President, International 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Thad Allen Huston officer: Chief Financial Officer 941 BLOOMFIELD ST, HOBOKEN NJ 07030
Seng Stacy Enxing director C/O HILL-ROM HOLDINGS, INC., SUITE 4100 180 NORTH STETSON AVENUE, CHICAGO IL 60601